CNBC December 20, 2024
Key Points
– The Food and Drug Administration approved Eli Lilly’s blockbuster weight loss drug Zepbound for treating patients with the most common sleep-related breathing disorder.
– The weekly injection is now the first drug treatment option cleared for patients with obesity and moderate-to-severe obstructive sleep apnea, which refers to breathing interrupted during sleep due to narrowed or blocked airways.
– The agency’s decision expands the use of Zepbound and could pave the way for Eli Lilly to gain broader insurance coverage for the treatment.
The Food and Drug Administration on Friday approved Eli Lilly‘s blockbuster weight loss drug Zepbound for treating patients with the most common sleep-related breathing disorder, expanding its use and possibly its insurance coverage in the...
Today's Sponsors
Today's Sponsor